At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance (PASI 100) and ≥10% weight loss In ...
At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance (PASI 100) and =10% weight loss In ...
Eli Lilly and Co. (NYSE: LLY) on Wednesday shared topline results from the landmark TOGETHER-PsO open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound ...
Add Yahoo as a preferred source to see more of our stories on Google. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.
Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy for the next 20 years. On February 18, Eli Lilly announced positive topline results from the Phase 3b TOGETHER-PsO trial, which ...
INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY) announced today that concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) demonstrated superior efficacy compared to Taltz alone in adults ...
The results from two recent clinical trials reinforce that treating obesity alongside inflammation can improve quality of life for many people with psoriatic diseases. In clinical trials involving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results